This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Cancer				
Cancer	Histone deacetylase (HDAC); interferon- γ (IFNG; IFN- γ)	<p>Mouse studies suggest combining HDAC inhibitors with IFN-γ stimulation may enhance antitumor efficacy. In immune-deficient mouse models of colon adenocarcinoma and lymphoma, an HDAC inhibitor had less potent antitumor activity than that seen in immunocompetent mice. In the lymphoma models, dual treatment with HDAC inhibitors and the Ifn-γ-inducing agent α-GalCer increased survival compared with treatment using either agent alone. Next steps could include testing combined HDAC inhibition and immune stimulation in clinical trials.</p> <p><i>SciBX</i> 6(47); doi:10.1038/scibx.2013.1342 Published online Dec. 12, 2013</p>	Patent and licensing status unavailable	<p>West, A.C. <i>et al. Cancer Res.</i>; published online Oct. 24, 2013; doi:10.1158/0008-5472.CAN-13-0890 Contact: Ricky W. Johnstone, Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia e-mail: ricky.johnstone@petermac.org</p>